NewAmsterdam Pharma Stock Hits 90-Plus RS Rating NewAmsterdam Pharma Stock Hits 90-Plus RS Rating · Investor's Business Daily INVESTOR'S BUSINESS DAILY and JULIE MAK Wed, Dec 11, 2024, 1:06 PM 1 min read In This Article: ADMA CORT CPRX NAMS NAMSW NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Continue Reading View Comments Terms and Privacy Policy Your Privacy Choices Utah Privacy Notice More Info Recommended Stories